Key Insights

Highlights

Success Rate

88% trial completion (above average)

Published Results

37 trials with published results (12%)

Research Maturity

143 completed trials (46% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

6.1%

19 terminated out of 309 trials

Success Rate

88.3%

+1.7% vs benchmark

Late-Stage Pipeline

8%

26 trials in Phase 3/4

Results Transparency

26%

37 of 143 completed with results

Key Signals

37 with results88% success19 terminated

Data Visualizations

Phase Distribution

221Total
Not Applicable (83)
Early P 1 (12)
P 1 (49)
P 2 (51)
P 3 (16)
P 4 (10)

Trial Status

Completed143
Recruiting59
Unknown47
Terminated19
Not Yet Recruiting16
Active Not Recruiting10

Trial Success Rate

88.3%

Benchmark: 86.5%

Based on 143 completed trials

Clinical Trials (309)

Showing 20 of 20 trials
NCT07085104Phase 1Recruiting

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07497087Phase 3RecruitingPrimary

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT06947460Phase 1Recruiting

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

NCT07295847Phase 1RecruitingPrimary

A Study of AZD0120 in Autoimmune Diseases

NCT05925803Phase 3Active Not RecruitingPrimary

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT06925542Phase 1Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

NCT06328777Phase 1RecruitingPrimary

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT07717060Not ApplicableNot Yet RecruitingPrimary

Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis

NCT03582800Phase 2RecruitingPrimary

Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study

NCT07596680Early Phase 1Not Yet Recruiting

CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases

NCT07697274Early Phase 1Not Yet RecruitingPrimary

Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial

NCT06544330Phase 1Active Not Recruiting

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

NCT05098704Phase 2Recruiting

Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk

NCT07676266Phase 1Not Yet Recruiting

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

NCT07515638Recruiting

Immun4Cure Cohort of Autoimmune Diseases

NCT05532865RecruitingPrimary

Prospective Cohort of Patients With Systemic Sclerosis at Brest University Hospital With Biobanking

NCT07038447Phase 1Enrolling By Invitation

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

NCT07649265Phase 1Not Yet Recruiting

A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

NCT07335562Phase 3RecruitingPrimary

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT04301596CompletedPrimary

Assessment of Nutritional Status in Systemic Sclerosis

Scroll to load more

Research Network

Activity Timeline